Astra Merck: Nancy Wysenski to VP-sales and Barry Greene to VP-marketing and customer services, filling roles vacated by VP-Sales and Marketing Matthew Emmens. Emmens was named acting CEO Jan. 17, replacing Wayne Yetter, who departed to lead Novartis' U.S. pharmaceuticals business ("The Pink Sheet" Feb. 3, T&G-1). Wysenski was executive director of field sales at Astra Merck; Greene had worked on process design for Astra Merck's sales and marketing organization as an associate partner with Andersen Consulting. Astra Merck also announces the promotions of VP-Drug Development Irwin Scher to chief medical officer and senior VP-drug development; VP-Portfolio Management Dave Brennan to senior VP-business operations; and Rob Cohen, VP-information technology, to chief information officer...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.
Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.
